3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
442
Rectal Neoplasms
209
Colonic Neoplasms
202
Pancreatic Neoplasms
133
Stomach Neoplasms
117
Neoplasm Metastasis
86
Esophageal Neoplasms
57
Carcinoma, Hepatocellular
41
Adenocarcinoma Of Esophagus
37
Neoplasms
36
Cholangiocarcinoma
27
Biliary Tract Neoplasms
23
Gastrointestinal Neoplasms
20
Gallbladder Neoplasms
20
Adenocarcinoma
19
Carcinoma, Non-Small-Cell Lung
16
Esophageal Squamous Cell Carcinoma
15
Liver Neoplasms
14
Bile Duct Neoplasms
14
Digestive System Neoplasms
9
Parkinson Disease 4, Autosomal Dominant Lewy Body
8
Colorectal Cancer Metastatic
8
Appendiceal Neoplasms
7
Peritoneal Neoplasms
6
Ovarian Neoplasms
6
Intestinal Neoplasms
6
Carcinoma
6
Breast Neoplasms
6
Lung Neoplasms
5
Carcinoma, Renal Cell
5
Interventions
durvalumab
2
Nivolumab
2
Gemcitabine
2
tremelimumab
1
regorafenib
1
nilotinib
1
neratinib
1
encorafenib
1
Valproic Acid
1
Taxes
1
Standard of Care
1
Radiomics
1
Practice Guidelines as Topic
1
Palliative Care
1
Oxaliplatin
1
Leucovorin
1
Hepatectomy
1
Folfox protocol
1
Fluorouracil
1
Clinical Trials, Phase II as Topic
1
Clinical Trials, Phase I as Topic
1
Clinical Trials as Topic
1
Cisplatin
1
Cetuximab
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease Progression
×
Leucovorin
×
Gastrointestinal
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts